CClinicalTrials.gg
Sign In
CompletedNCT05110976Updated Aug 30, 2023

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

A Phase 1 interventional study of AZD8630 and Placebo in Asthma, sponsored by AstraZeneca. Completed at 29 sites in 3 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 2 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled corticosteroids / Long-acting beta-agonists (Part B)

Read the detailed description

The study is divided in 2 parts, A and B.

Part A will be conducted in healthy adults, whereas Part B will be conducted in adult asthma patients on medium/high dose inhaled corticosteroids (ICS)/long-acting beta-agonists (LABA) to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of AZD8630 by dry powder inhaler (DPI) administration. Part A includes the assessment of the PK and safety of intravenous (IV) AZD8630. Part A consists of single ascending dose (SAD) and multiple ascending dose (MAD) cohorts in sequential order and Part B will be evaluating multiple dose levels.

Part A: This part will consist 4 sub-parts and will include healthy participants and healthy participants of Chinese and Japanese ethnicity. These participants will randomized to receive AZD8630 and to receive placebo.

  • Sub-Part A1, SAD in healthy participants (one cohort in Sub-Part A1 will receive IV AZD8630 [IV formulation])
  • Sub-Part A2, SAD in healthy participants of Chinese and Japanese ethnicity
  • Sub-Part A3, MAD in healthy participants
  • Sub-Part A4, MAD in healthy participants of Chinese and Japanese ethnicity

Part B: Adult asthma patients will be randomized to one of 3 inhaled dose levels of AZD8630 or placebo.

The expected duration of study participation for each participants in the part A is up to 87 days, and each patients in the Part B is up to 70 days.

02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Healthy adult participants
  • Healthy participants of Chinese and Japanese ethnicity
  • Corticosteroids Beta-agonists
  • Multiple ascending dose
  • Single ascending dose
03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 170 is above the median of 83 across 2,752 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Part A (Healthy participants):

  1. Healthy participants aged 18 to 55 years, inclusive:

    1. Japanese participants must be aged 20 to 55 years, inclusive
    2. Chinese participants must be aged 18 to 45 years, inclusive
  2. Females must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test on admission to the Clinical Unit, must not be lactating, and must be of non childbearing potential, confirmed at the Screening Visit
  3. Have a body mass index (BMI) between 18 and 30 kg/m\^2 inclusive and weigh at least 45 kg.
  4. Healthy participant must have a forced expiratory volume in 1 second (FEV1) ≥ 80% of the predicted value regarding age, height, gender, and ethnicity at the Screening Visit.
  5. Male participants and their women of childbearing potential partners (WOCPB) should be willing to use highly effective contraception measures and male participants should refrain from donating sperm or fathering a child from the first day of dosing until 3 months after the study Follow up Visit.
  6. Part A2 and Part A4 (Chinese population only): Chinese participants must have been born in China, have all parents and grandparents of Chinese origin, and not have lived outside of China for more than 10 years.
  7. Part A2 and Part A4 (Japanese population only): Japanese participants must have been born in Japan, have all parents and grandparents of Japanese origin, and not have lived outside of Japan for more than 10 years.

Part B (Participants with Asthma):

  1. Male and female including WOCBP participants with asthma aged 18 to 75 years inclusive, with suitable veins for cannulation or repeated venipuncture.
  2. Have a BMI between 18 and 35 kg/m\^2 inclusive and weigh at least 45 kg.
  3. Confirmed physician-led diagnosis of asthma for > 6 months before the Screening Visit.
  4. Any of the following assessments within the last 10 years to confirm variable airflow obstruction: Variability between clinic visits: FEV1 > 12% and 200 mL; Response to 4 weeks' anti-inflammatory therapy: FEV1 > 12% and 200 mL; Exercise challenge test: FEV1 fall > 10% and 200mL; Methacholine challenge test: FEV1 ≥ 20% fall at \< 8 mg/mL; Indirect challenge test: FEV1 ≥ 15% fall; Or in the screening period: Variability between clinic visits: FEV1 > 12% and 200 mL; Peak expiratory flow rate (PEFR) for 2 weeks during run-in: PEFR average daily variability > 10%.
  5. Pre-bronchodilator FEV1 ≥ 40% and \< 85% predicted at the Screening Visit.
  6. Have a fractional exhaled nitric oxide (FeNO) of ≥ 35 ppb at the Screening Visit and ≥ 30 ppb at randomisation.
  7. Asthma Control Questionnaire -5 score of ≥ 0.75 and ≤ 3.0 at screening.

  8. During 7 consecutive days within screening, immediately prior to randomisation demonstrates ≥ 65% adherence to each of the following:

    1. Once daily home FeNO
    2. Twice daily home spirometry measurements
    3. Twice daily entries in the eDiary
  9. Females must have a negative serum pregnancy test at the Screening Visit. Additionally, WOCBP must have a negative urine pregnancy test at Visit 2 (prior to randomisation) and must not be lactating.
  10. Male participants and their WOCBP partners should be willing to use highly effective contraception measures and male participants should refrain from donating sperm or fathering a child from the first day of dosing until 3 months after the study Follow-up Visit.
  11. WOCBP must be willing to use highly effective contraception measures from the first day of dosing until 3 months after the study Follow up Visit.

Exclusion criteria

Exclusion Criteria:

Part A (Healthy participants)

  1. History of following: any clinically important disease or disorder; any upper or lower respiratory tract infection during screening period; active tuberculosis or current positive result for Interferon gamma release assay at screening; clinically significant history of atopy or allergy to common allergens including house dust mite and pollens, or a history of childhood asthma.
  2. Active or previous hepatitis B, hepatitis C, or Human immunodeficiency virus at the Screening Visit, and other latent or chronic infections.
  3. History of severe COVID-19 (Coronavirus disease 2019) infection requiring hospitalization
  4. SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) first vaccination within 30 days prior to screening.
  5. SARS-CoV-2 second or booster vaccination within 10 days of screening.
  6. Unwilling to defer SARS-CoV-2 vaccination during the study period.
  7. History of cancer within last 10 years (20 years for breast cancer) except for basal and squamous cell carcinoma of skin or in situ carcinoma of cervix treated and considered cured. Any history of lymphoma is not allowed.
  8. Have received live or live attenuated vaccine in 4 weeks prior to randomisation.
  9. History of acquired or inherited immunodeficiency disorders including but not limited to HIV, COVID-19, or taking immune replacement therapy.
  10. C-reactive protein above upper limit of laboratory reference range
  11. Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results and abnormal vital signs at the Screening Visit.
  12. Current smokers or those who have smoked or used nicotine or inhalational cannabis/marijuana products. History of alcohol abuse or drug abuse.
  13. Use of any prescribed or nonprescribed medication during the 2 weeks prior to the first administration of investigational medicinal product.
  14. Has received another new chemical entity.
  15. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD8630.
  16. History of anaphylaxis to any previous biological therapy.
  17. Participants who have previously received AZD8630.

Part B (Participants with Asthma):

  1. History of following: any clinically important disease or disorder; any chronic respiratory disorders (except asthma) such as Chronic obstructive pulmonary disease, bronchiectasis, or IPF; clinically significant lower respiratory tract infection not resolved within 4 weeks prior to screening.
  2. Acute exacerbation of asthma requiring hospitalisation and/or attendance at an emergency department and/or systemic corticosteroids within 6 weeks of randomisation.
  3. History of active TB or a current positive result for IGRA at screening.
  4. History of severe COVID-19 infection requiring hospitalisation.
  5. SARS-CoV-2 first vaccination within 30 days prior to screening.
  6. SARS-CoV-2 second or booster vaccination within 10 days of screening.
  7. Confirmed COVID-19 infection during screening, prior to randomisation.
  8. History of cancer within the last 10 years (20 years for breast cancer) except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured. Any history of lymphoma is not allowed.
  9. Have received live or live attenuated vaccine in the 4 weeks prior to randomisation.
  10. C-reactive protein above the upper limit of laboratory reference range at screening.
  11. Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results, and abnormal vital signs at the Screening Visit.
  12. Current smokers or those who have smoked or used nicotine or inhalational cannabis/marijuana products. History of alcohol or drug abuse.
  13. Positive screen for drugs of abuse or cotinine (nicotine) prior to randomisation.
  14. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks before first administration of study drug.
  15. Use of any prescribed or nonprescribed medication during the 2 weeks prior to the first administration of study drug.
  16. Use of following medicines within specified time before Screening: (a) Any biologics for asthma within 6 months prior to Screening; (b) Systemic or intranasal steroids within 4 weeks prior to Screening; (c) Xanthines, anticholinergics, or cromoglycate within 1 week prior to Screening; (d) Short acting bronchodilator other than for rescue and within 12 hours prior to Screening and Day -1 assessments.
  17. History of anaphylaxis or ongoing clinically important serious allergy, or history of hypersensitivity or anaphylaxis to drugs with a similar chemical structure or class to AZD8630.
  18. History of anaphylaxis to any previous biological therapy.
  19. Pregnancy or intention to become pregnant during course of study, breastfeeding, or unwillingness to use a highly effective method of contraception throughout study in female participants of childbearing potential or lactating woman.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Part A1: SAD (AZD8630)

    Healthy participants will receive single inhaled doses 1 to 5 of AZD8630.

    Drug: AZD8630

  • Experimental
    Part A1: IV (AZD8630)

    Healthy participants will receive a single IV dose of AZD8630.

    Drug: AZD8630

  • Placebo comparator
    Part A1: IV (Placebo)

    Healthy participants will receive single IV dose of Placebo.

    Drug: Placebo

  • Experimental
    Part A2: SAD (AZD8630)

    Healthy participants of Chinese and Japanese ethnicity will receive single inhaled dose 5 of AZD8630.

    Drug: AZD8630

  • Experimental
    Part A3: MAD (AZD8630)

    Healthy participants will receive once daily inhaled doses 3, 4, and 5 of AZD8630.

    Drug: AZD8630

  • Experimental
    Part A4: MAD (AZD8630)

    Healthy participants of Chinese and Japanese ethnicity will receive once daily inhaled dose 5 of AZD8630.

    Drug: AZD8630

  • Placebo comparator
    Part A: SAD (Placebo)

    Healthy participants and healthy participants of Chinese and Japanese ethnicity will receive single inhaled doses of placebo.

    Drug: Placebo

  • Placebo comparator
    Part A: MAD (Placebo)

    Healthy participants and healthy participants of Chinese and Japanese ethnicity will receive once daily inhaled dose of placebo.

    Drug: Placebo

  • Experimental
    Part B (AZD8630)

    Participants with asthma will be randomized to one of 3 inhaled dose levels 3, 6, and 7 of AZD8630 once daily.

    Drug: AZD8630

  • Placebo comparator
    Part B (Placebo)

    Participants with asthma will receive once daily inhaled dose of placebo.

    Drug: Placebo

Interventions

  • DrugAZD8630

    Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.

  • DrugPlacebo

    Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.

06

What researchers measure

Primary outcomes

  1. Part A and Part B: Number of participants with adverse events

    Safety and tolerability of inhaled AZD8630 in healthy participants and participants with asthma will be assessed.

    Time frame: Until Follow-up (FU) Visit/Early Termination (ET) Visit (Part A: 7-day post-dose for SAD; 10-day post-last dose for MAD) and Part B: Until FU Visit/ET Visit (10-day post-last dose)

  2. Part A (IV cohort): Time to reach maximum observed concentration (tmax) of AZD8630

    tmax of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  3. Part A (IV cohort): Time of last observed quantifiable concentration (tlast) of AZD8630

    tlast of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  4. Part A (IV cohort): Maximum observed serum (peak) drug concentration (Cmax) of AZD8630

    Cmax of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  5. Part A (IV cohort): Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630

    AUC(0-24) of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  6. Part A (IV cohort): Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630

    AUClast of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  7. Part A (IV cohort): Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630

    AUCinf of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  8. Part A (IV cohort): Terminal rate constant (λz) of AZD8630

    λz of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  9. Part A (IV cohort): Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of AZD8630

    t1/2λz) of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  10. Part A (IV cohort): Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630

    MRTinf of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  11. Part A (IV cohort): Total body clearance of drug from serum after IV administration (CL) of AZD8630

    CL of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  12. Part A (IV cohort): Volume of distribution at steady state (Vss) of AZD8630

    Vss of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  13. Part A (IV Cohort): Volume of distribution of drug from serum after IV administration (Vz) of AZD8630

    Vz of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.

    Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)

  14. Part A (IV Cohort): Number of participants with adverse events

    Safety and tolerability of IV AZD8630 in healthy participants will be assessed.

    Time frame: Until Follow-up (FU) Visit/Early Termination (ET) Visit (7-day post-dose)

Secondary outcomes

  1. Part A and Part B: Time to reach maximum observed concentration (tmax) of AZD8630

    tmax of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  2. Part A (A1 and A2 only): Time of last observed quantifiable concentration (tlast) of AZD8630

    tlast of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose)

  3. Part A and Part B: Maximum observed serum (peak) drug concentration (Cmax) of AZD8630

    Cmax of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  4. Part A and Part B: Maximum observed serum (peak) drug concentration divided by the lung-delivered dose (LDD) [Cmax/D] of AZD8630

    Cmax/D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  5. Part A and Part B: Concentration at the end of the dosing interval (Ctrough) [repeat dose only] of AZD8630

    Ctrough of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  6. Part A and Part B: Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630

    AUC(0-24) of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), and Day 1 for MAD and Part B

  7. Part A and Part B: Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose divided by the LDD [AUC(0-24)/D] of AZD8630

    AUC(0-24)/D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), and Day 1 for MAD and Part B

  8. Part A: Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630

    AUClast of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose)

  9. Part A: Area under the serum concentration-time curve from time zero to time of last quantifiable drug concentration divided by the LDD (AUClast/D) of AZD8630

    AUClast/D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose)

  10. Part A and Part B: Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630

    AUCinf of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), and Day 1 for MAD and Part B

  11. Part A and Part B: Area under the serum concentration-time curve from time zero extrapolated to infinity divided by the LDD (AUCinf /D) of AZD8630

    AUCinf /D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), and Day 1 for MAD and Part B

  12. Part A and Part B: Area under serum concentration-time curve in the dosing interval t (AUCt) of AZD8630

    AUCt of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  13. Part A and Part B: Area under serum concentration-time curve in the dosing interval t divided by the LDD (AUCt/D) of AZD8630

    AUCt/D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  14. Part A and Part B: Terminal rate constant (λz) of AZD8630

    λz of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  15. Part A and Part B: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of AZD8630

    t1/2λz of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  16. Part A and Part B: Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630

    MRTinf of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  17. Part A and Part B: Apparent total body clearance of drug from serum after extravascular administration (inhalation administration only) [CL/F] of AZD8630

    CL/F of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  18. Part A and Part B: Apparent volume of distribution following extravascular administration based on terminal phase (inhalation administration only) [Vz/F] of AZD8630

    Vz/F of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)

  19. Part A and Part B: Accumulation ratio based upon AUCt [Rac(AUC)] of AZD8630

    Rac(AUC) of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (MAD) Day 14; Part B- Day 28

  20. Part A and Part B: Accumulation ratio based upon Cmax [Rac(Cmax)] of AZD8630

    Rac(Cmax) of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.

    Time frame: Pre-dose and Post-dose: Part A- (MAD) Day 14; Part B- Day 28

  21. Part A and Part B: Number of participants with presence of anti-drug antibodies (ADAs)

    Immunogenicity of AZD8630 following single and multiple dose administration will be characterized.

    Time frame: Pre-dose: Part A- (SAD) Days 1 to 3 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1, 7, 14, and 28, and FU Visit/ ET Visit (10-day post-last dose)

  22. Part B: Change from baseline in fractional exhaled nitric oxide (FeNO) levels

    The PD effect of AZD8630 on FeNO versus placebo following daily inhaled AZD8630 will be assessed.

    Time frame: From Screening (Up to days 28 before Day 1) until Day 29 (end of the treatment visit)

07

Study locations

29 sites
  • Research Site
    Tempe, Arizona 85283, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    San Jose, California 95117, United States
  • Research Site
    Homestead, Florida 33030, United States
  • Research Site
    Miami, Florida 33122, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Miami, Florida 33175, United States
  • Research Site
    Boise, Idaho 83706, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    North Dartmouth, Massachusetts 02747, United States
  • Research Site
    Ann Arbor, Michigan 48105, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Toledo, Ohio 43617, United States
  • Research Site
    Portland, Oregon 97202, United States
  • Research Site
    El Paso, Texas 79903, United States
  • Research Site
    Berlin, 10119, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Großhansdorf, 22927, Germany
  • Research Site
    Lübeck, 23552, Germany
  • Research Site
    Magdeburg, 39120, Germany
  • Research Site
    Wiesbaden, 65187, Germany
  • Research Site
    Bradford, BD9 6RJ, United Kingdom
  • Research Site
    London, HA1 3UJ, United Kingdom
  • Research Site
    London, W12 0HS, United Kingdom
  • Research Site
    Manchester, M23 9QZ, United Kingdom
  • Research Site
    Portsmouth, PO6 3LY, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05110976
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Dec 16, 2021
Primary completion
Aug 2, 2023
Completion
Aug 2, 2023
Last update
Aug 30, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Asthma→

Other studies from this sponsor

AstraZeneca

Start the discussion